The molecular basis of HLA-unrestricted recognition is not known. Peripheral blood leukocytes stimulated with IL-2 can express the ability to recognize and kill a variety of targets in a HLA-unrestricted manner. Two models have been proposed to explain the molecular basis of HLA- unrestricted and TCR-independent recognition. The first model states that activation by IL-2 induces the expression of unique LAK-like receptors that recognize and blind common target structures. However, no purely NK or LAK cell-specific receptor has been characterized; thus this model remains to be confirmed. The alternative model states that HLA- unrestricted cytotoxicity is mediated by multiple monomorphic receptors that recognize different ligands on the target cells. The number of different types of molecules that are implicated in mediating LAK-tumor cell interaction supports the second hypothesis. I have recently shown that a subset of the CD3+LAK cells are stimulated by tumor cells to produce tumor necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma). The stimulation of these T cells is not dependent on target cell-expression of HLA antigens. My preliminary data support previously published reports that leukocyte integrins may be important mediators of such HLA-unrestricted recognition. The major objectives of this project are: (1) to determine whether monomorphic integrins and cell adhesion molecules (CAMs) are sufficient to fully mediate the stimulation of CD3+LAK cells to produce TNF-alpha and IFN- gamma, or if other, possibly LAK cell-associated molecules, are necessary for maximum stimulation. To address the possibility that the CD3+LAK cells are heterogeneous with respect with their ability to recognize tumor cells cloned CD3+LAK and will be used in some of these studies. (2) to determine whether the ligands that stimulate the production of TNF-alpha and INF- gamma by CD3+LAK cells, also mediate the ability of cloned CD3+LAK and purified IL-2 activated-NK cells to lyse, can tumor cells. (3)To determine whether normal cells, which are reported to be resistant to LAK cell- mediated lysis, can stimulate LAK cell to produce TNF-alpha and IFN-gamma, and, if so, whether that ability is correlated with the expression of the same stimulatory ligands as those originally identified on tumor cells. The basic research that I am proposing will utilize LAK cells as an experimental model for studying HLA-unrestricted recognition. These studies will allow me to define the molecules that can trigger IL-2 activated T cells to produce TNF-alpha and IFN-gamma. The identify of these stimulatory molecules will provide insights into the roles LAK cells and the released cytokines play in vivo.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
First Independent Research Support & Transition (FIRST) Awards (R29)
Project #
5R29CA053805-03
Application #
3460122
Study Section
Experimental Immunology Study Section (EI)
Project Start
1991-08-01
Project End
1995-07-31
Budget Start
1993-08-01
Budget End
1994-07-31
Support Year
3
Fiscal Year
1993
Total Cost
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60612